Among adults with COPD and type 2 inflammation, having a history of cardiovascular or metabolic disease did not change ...
Merck completes $10B acquisition of Verona Pharma, adding Ohtuvayre — the first new inhaled COPD therapy in over 20 years.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback